Bone marrow necrosis following treatment for chronic myeloid leukaemia with STI-571
Access status:
Open Access
Type
Article, LetterAbstract
Imatinib mesylate has recently been licensed for the treatment of selected patients with chronic myelogenous leukemia (CML). 1We report a case of bone marrow necrosis secondary to imatinib mesylate therapy in a patient with accelerated-phase CMLImatinib mesylate has recently been licensed for the treatment of selected patients with chronic myelogenous leukemia (CML). 1We report a case of bone marrow necrosis secondary to imatinib mesylate therapy in a patient with accelerated-phase CML
See less
See less
Date
2002-01-01Publisher
Massachusetts Medical SocietyCitation
Burton C, Azzi A, Kerridge I H. Bone marrow necrosis following treatment for chronic myeloid leukaemia with STI-571. N Engl J Med; 2002; 346(9):713.Share